News Release Details

Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 10, 2020 at 7:00 AM EST

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, announced today that Pete Salzmann, Chief Executive Officer, will provide a corporate overview at the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27 in New York City.

9th Annual Global Healthcare Conference
Date: Tuesday, February 25th
Time: 3:00pm Eastern Time
Webcast: 

The presentation will be available via webcast and can be accessed at the Investor
Relations section of the Company’s website, located at www.immunovant.com

About Immunovant, Inc.
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Contact:
John Strumbos, Ph.D., MBA
Vice President, Finance
Immunovant, Inc.
info@immunovant.com

 

immunovant_logoV7_RGB.png

Source: Immunovant